References

akusherstvo

Obstetrics, Gynecology and Reproduction

Акушерство, Гинекология и Репродукция

2313-73472500-3194

IRBIS LLC

10.17749/2313-7347/ob.gyn.rep.2022.370

akusherstvo-1521

Research Article

REVIEW ARTICLES

НАУЧНЫЕ ОБЗОРЫ

Antithrombotic therapy in COVID-19 patients

Антитромботическая терапия у пациентов с COVID-19

https://orcid.org/0000-0001-7441-2778

Слуханчук

Е. В.

Slukhanchuk

E. V.

Слуханчук Екатерина Викторовна – к.м.н., доцент кафедры акушерства, гинекологии и перинатальной медицины Клинического института детскогоздоровья имени Н.Ф. Филатова

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Ekaterina V. Slukhanchuk – MD, PhD, Associate Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

ekaterina@ginekologhirurg.ru

https://orcid.org/0000-0001-8404-1042

Бицадзе

В. О.

Bitsadze

V. O.

Бицадзе Виктория Омаровна – д.м.н., профессор РАН, профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова

Scopus Author ID: 6506003478

Researcher ID: F-8409-2017.

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Victoria O. Bitsadze – MD, Dr Sci Med, Professor of RAS, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute ofChildren’s Health

Scopus Author ID: 6506003478

Researcher ID: F-8409-2017.

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

https://orcid.org/0000-0002-0725-9686

Хизроева

Д. Х.

Khizroeva

J. Kh.

Хизроева Джамиля Хизриевна – д.м.н., профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детскогоздоровья имени Н.Ф. Филатова

Scopus Author ID: 57194547147

Researcher ID: F-8384-2017.

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Jamilya Kh. Khizroeva – MD, Dr Sci Med, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health

Scopus Author ID: 57194547147

Researcher ID: F-8384-2017.

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

https://orcid.org/0000-0002-3628-0804

Третьякова

М. В.

Tretyakova

M. V.

Третьякова Мария Владимировна – к.м.н., врач акушер-гинеколог, ассистент кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Maria V. Tretyakova – MD, PhD, Obstetrician-Gynecologist, Assistant, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

https://orcid.org/0000-0002-9783-1796

Шкода

А. С.

Shkoda

A. S.

Шкода Андрей Сергеевич – д.м.н., профессор, главный врач

123423 Москва, ул. Саляма Адиля, д. 2/44

Andrey S. Shkoda – MD, Dr Sci Med, Professor, Chief Physician

2/44 Salyama Adilya Str., Moscow 123423

https://orcid.org/0000-0002-3367-9844

Блинов

Д. В.

Blinov

D. V.

Блинов Дмитрий Владиславович – к.м.н., ассистент кафедры спортивной медицины и медицинской реабилитации Института клинической медицины имени Н.В. Склифосовского; руководитель по медицинским и научным вопросам; доцент кафедры спортивной, физической и реабилитационной медицины

Scopus Author ID: 6701744871

Researcher ID: E-8906-2017

RSCI: 9779-8290.

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4;

127006 Москва, ул. Садовая-Триумфальная, д. 4–10;

123056 Москва, 2-я Брестская ул., д. 5, с. 1–1а

Dmitry V. Blinov – MD, PhD, MBA, Assistant, Department of Sports Medicine and Medical Rehabilitation, Sklifosovsky Institute of Clinical Medicine; Head of Medical and Scientific Affairs; Associate Professor, Department of Sports

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991;

4–10 Sadovaya-Triumfalnaya Str., Moscow 127006;

5 bldg. 1–1a, 2-ya Brestskaya Str., Moscow 123056

https://orcid.org/0000-0001-5888-0774

Цибизова

В. И.

Tsibizova

V. I.

Цибизова Валентина Ивановна – к.м.н., врач акушер-гинеколог НИЛ оперативной гинекологии Института перинатологии и педиатрии, врач отделения функциональной ультразвуковой диагностики

197341 Санкт-Петербург, ул. Аккуратова, д. 2

Valentina I. Tsibizova – MD, PhD, Obstetrician-Gynecologist, Research Laboratory of Operative Gynecology, Institute of Perinatology and Pediatrics; Physician, Department of Functional and Ultrasound Diagnostics

2 Akkuratova Str., Saint Petersburg 197341

Цзиньбо

Ч.

Jinbo

Цзиньбо Чжао – студент Института клинической медицины имени Н.В. Склифосовского

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Zhao Jinbo – Student, Sklifosovsky Institute of Clinical Medicine

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

Шина

С.

Sheena

Шина Соперна – студент Института клинической медицины имени Н.В. Склифосовского

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Sheena Soperna – Student, Sklifosovsky Institute of Clinical Medicine

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

https://orcid.org/0000-0002-8512-9043

Шульман

С.

Sсhulman

Шульман Сэм – д.м.н., профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова; профессор медицинского факультета Научно-исследовательского института тромбоза и атеросклероза; иностранный член РАН

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Sam Schulman – MD, Dr Sci Med, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health; Professor, Department of Medicine, Thrombosis and Atherosclerosis Research Institute

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991;

1280 Main Street West, Hamilton, Ontario L8S 4K1

https://orcid.org/0000-0002-9899-9910

Гри

Ж.-К.

Gris

J.-K.

Гри Жан-Кристоф – д.м.н., профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова; профессор гематологии, зав. лабораторией гематологии факультета биологических и фармацевтических наук; иностранный член РАН

Scopus Author ID: 7005114260

Researcher ID: AAA-2923-2019.

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Jean-Christophe Gris – MD, Dr Sci Med, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health; Professor of Haematology, Head of the Laboratory of Haematology, Faculty of Biological and Pharmaceutical Sciences; Foreign Member of RAS

Scopus Author ID: 7005114260

Researcher ID: AAA-2923-2019.

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991;

163 Rue Auguste Broussonnet, Montpellier 34090

https://orcid.org/0000-0002-9576-1368

Элалами

И.

Elalamy

Элалами Исмаил – д.м.н., профессор кафедры акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова; профессор; директор гематологии Центра Тромбозов

Scopus Author ID: 7003652413

Researcher ID: AAC-9695-2019.

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Ismail Elalamy – MD, Dr Sci Med, Professor, Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health; Professor; Director of Hematology, Department of Thrombosis Center

Scopus Author ID: 7003652413

Researcher ID: AAC-9695-2019.

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991;

12 Rue de l’École de Médecine, Paris 75006;

4 Rue de la Chine, Paris 75020

https://orcid.org/0000-0001-7415-4633

Макацария

А. Д.

Makatsariya

A. D.

Макацария Александр Давидович – д.м.н., профессор, академик РАН, зав. кафедрой акушерства, гинекологии и перинатальной медицины Клинического института детского здоровья имени Н.Ф. Филатова

Scopus Author ID: 57222220144

Researcher ID: M-5660-2016.

119991 Москва, ул. Большая Пироговская, д. 2, стр. 4

Alexander D. Makatsariya – MD, Dr Sci Med, Academician of RAS, Professor, Head of the Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health

Scopus Author ID: 57222220144

Researcher ID: M-5660-2016.

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет)РоссияSechenov UniversityRussian Federation

ГБУЗ «Городская клиническая больница № 67 имени Л.А. Ворохобова Департамента здравоохранения города Москвы»РоссияVorokhobov City Clinical Hospital № 67, Moscow City Healthcare DepartmentRussian Federation

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет); Институт Превентивной и Социальной Медицины; АНО ДПО «Московский медико-социальный институт имени Ф.П. Гааза»РоссияSechenov University; Institute for Preventive and Social Medicine; Moscow Haass Medical – Social InstituteRussian Federation

ФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research Centre, Health Ministry of Russian FederationRussian Federation

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет); Университет МакмастераРоссияSechenov University; McMaster UniversityRussian Federation

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет); Университет МонпельеРоссияSechenov University; University of MontpellierRussian Federation

ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет); Медицинский Университет Сорбонны; Госпиталь ТенонРоссияSechenov University; Medicine Sorbonne University; Hospital TenonRussian Federation

2022

15012023

166718731

2023

Слуханчук Е.В., Бицадзе В.О., Хизроева Д.Х., Третьякова М.В., Шкода А.С., Блинов Д.В., Цибизова В.И., Цзиньбо Ч., Шина С., Шульман С., Гри Ж., Элалами И., Макацария А.Д.

Slukhanchuk E.V., Bitsadze V.O., Khizroeva J.K., Tretyakova M.V., Shkoda A.S., Blinov D.V., Tsibizova V.I., Jinbo Z., Sheena S., Sсhulman S., Gris J., Elalamy I., Makatsariya A.D.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.gynecology.su/jour/article/view/1521

Recently, there have been published the data of large randomized trials on the use of antithrombotic agents for reducing a risk of thromboembolic complications, multiple organ failure and mortality in COVID-19 patients. However, principles of selecting optimal therapy remain open. Strategies for the use of antithrombotic drugs in outpatient and inpatient settings, thromboprophylaxis in specific patient populations, and treatment of acute thrombosis in hospitalized COVID-19 patients are being developed. In October 2021, the International Society on Thrombosis and Hemostasis (ISTH) formed an interdisciplinary international panel of experts to develop recommendations for use of anticoagulants and antiplatelet agents in COVID-19 patients. Expert opinions are published. Here, we summarize all the publications available globally at the present time on this issue, obtained by using the principles of evidence-based medicine.

В течение последнего времени были опубликованы результаты крупных рандомизированных исследований, посвященных использованию антитромботических средств для снижения риска тромбоэмболических осложнений, полиорганной недостаточности и смертности у пациентов с COVID-19. Однако принципы оптимального подбора терапии все еще остаются открытыми. Продолжается разработка стратегии антитромботической терапии у амбулаторных и стационарных пациентов, антитромботической профилактики в особых группах пациентов, а также стратегий терапии острого тромбоза у госпитализированных пациентов с COVID-19. В октябре 2021 г. Международное общество по тромбозу и гемостазу (англ. International Society on Thrombosis and Hemostasis, ISTH) сформировало междисциплинарную международную группу экспертов для разработки рекомендаций по использованию антикоагулянтов и антиагрегантов у пациентов с COVID-19. Заключения экспертов также опубликованы. В настоящем обзоре суммирована вся имеющаяся в мировой литературе в настоящий момент времени информация по данной проблеме, полученная с использованием принципов доказательной медицины.

коронавирустяжелый острый респираторный синдромSARS-CoV-2антитромботическая терапияантиагрегантыантикоагулянтыCOVID-19

coronavirussevere acute respiratory syndromeSARS-CoV-2antithrombotic therapyantiaggregantsanticoagulantsCOVID-19

References1

Schulman S., Sholzberg M., Spyropoulos A.C. et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2022;20(10):2214–25. https://doi.org/10.1111/jth.15808.

Spyropoulos A.C., Connors J.M., Douketis J.D. et al. Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022;20(10):2226–36. https://doi.org/10.1111/jth.15809.

Piazza G., Campia U., Hurwitz S. et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2060–72. https://doi.org/10.1016/j.jacc.2020.08.070.

Giannis D., Barish M.A., Goldin M. et al. Incidence of venous thromboembolism and mortality in patients with initial presentation of COVID-19. J Thromb Thrombolysis. 2021;51(4):897–901. https://doi.org/10.1007/s11239-021-02413-7.

Ilowite J., Lisker G., Greenberg H. Digital health technology and telemedicine-based hospital and home programs in pulmonary medicine during the COVID-19 pandemic. Am J Ther. 2021;28(2):e217–e223. https://doi.org/10.1097/MJT.0000000000001342.

Jnr B.A. Use of telemedicine and virtual care for remote treatment in response to COVID-19 pandemic. J Med Syst. 2020;44(7):132. https://doi.org/10.1007/s10916-020-01596-5.

Connors J.M., Brooks M.M., Sciurba F.C. et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA. 2021;326(17):1703–12. https://doi.org/10.1001/jama.2021.17272.

Gonzalez-Ochoa A.J., Raffetto J.D., Hernández A.G. et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemost. 2021;121(7):944–54. https://doi.org/10.1055/a-1414-5216.

Hozayen S.M., Zychowski D., Benson S. et al. Outpatient and inpatientanticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. EClinicalMedicine. 2021;41:101139. https://doi.org/10.1016/j.eclinm.2021.101139.

Flam B., Wintzell V., Ludvigsson J.F. et al. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med. 2021;289(3):411–9. https://doi.org/10.1111/joim.13205.

Rivera-Caravaca J.M., Buckley B.J., Harrison S.L. et al. Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thromb Res. 2021;205:1–7. https://doi.org/10.1016/j.thromres.2021.06.014.

Kleindorfer D.O., Towfighi A., Chaturvedi S. et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–e467. https://doi.org/STR.0000000000000375.

Rentsch C.T., Beckman J.A., Tomlinson L. et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021;372:n311. https://doi.org/10.1136/bmj.n311.

Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–9. https://doi.org/10.1001/jama.2020.6775.

Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.

Tritschler T., Mathieu M.-E., Skeith L. et al. Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost. 2020;18(11):2958–67. https://doi.org/10.1111/jth.15094.

ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Patrick R Lawler P.R., Goligher E.C., Berger J.S. et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385(9):790–802. https://doi.org/10.1056/NEJMoa2105911.

Spyropoulos A.C., Goldin M., Giannis D. et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612–20. https://doi.org/10.1001/jamainternmed.2021.6203.

Sholzberg M., Tang G.H., Rahhal H. et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400. https://doi.org/10.1136/bmj.n2400.

Battistoni I., Francioni M., Morici N. et al. Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. J Cardiovasc Med (Hagerstown). 2022;23(4):264–71. https://doi.org/10.2459/JCM.0000000000001284.

Cohen S.L., Gianos E., Barish M.A. et al. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost. 2021;121(8):1043–53. https://doi.org/10.1055/a-1366-9656.

Di Castelnuovo A., Costanzo S., Antinori A. et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study. Thromb Haemost. 2021;121(8):1054–65. https://doi.org/10.1055/a-1347-6070.

Ionescu F., Jaiyesimi I., Petrescu I. et al. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis. Eur J Haematol. 2021;106(2):165–74. https://doi.org/10.1111/ejh.13533.

Sholzberg M., da Costa B.R., Tang G.H. et al. Randomized trials of therapeutic heparin for COVID-19: a meta-analysis. Res Pract Thromb Haemost. 2021;5(8):e12638. https://doi.org/10.1002/rth2.12638.

Gonzalez-Porras J.R., Belhassen-Garcia M., Lopez-Bernus A. et al. Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study. Sao Paulo Med J. 2021;140(1):123–33. https://doi.org/10.1590/1516-3180.2021.0098.R1.08062021.

Meizlish M.L., Goshua G., Liu Y. et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity scorematched analysis. Am J Hematol. 2021;96(4):471–9. https://doi.org/10.1002/ajh.26102.

Morici N., Podda G., Birocchi S. et al. Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. Eur J Clin Invest. 2022;52(5):e13735. https://doi.org/10.1111/eci.13735.

Smadja D.M., Bonnet G., Gendron N. et al. Intermediate- vs. standarddose prophylactic anticoagulation in patients with COVID-19 admitted in medical ward: A propensity score-matched cohort study. Front Med (Lausanne). 2021;8:747527. https://doi.org/10.3389/fmed.2021.747527.

Lopes R.D., de Barros E. Silva P.G.M., Furtado R.H.M. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397(10291):2253–63. https://doi.org/10.1016/S0140-6736(21)01203-4.

RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10320):143–51. https://doi.org/10.1016/S0140-6736(21)01825-0.

Berger J.S., Kornblith L.Z., Gong M.N.et al. Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial. JAMA. 2022;327(3):227–36. https://doi.org/10.1001/jama.2021.23605.

Shen L., Qiu L., Liu D. et al. The association of low molecular weight heparin use and in-hospital mortality among patients hospitalized with COVID-19. Cardiovasc Drugs Ther. 2022;36(1):113–20. https://doi.org/10.1007/s10557-020-07133-3.

Poli D., Antonucci E., Ageno W. et al. Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register. Intern Emerg Med. 2022;17(4):1013–21. https://doi.org/10.1007/s11739-021-02891-w.

Zinellu A., Paliogiannis P., Carru C., Mangoni A.A. INR and COVID-19 severity and mortality: A systematic review with meta-analysis and metaregression. Adv Med Sci. 2021;66(2):372–80. https://doi.org/10.1016/j.advms.2021.07.009.

Fumagalli S., Trevisan C., Del Signore S. et al. COVID-19 and atrial fibrillation in older patients: does oral anticoagulant therapy provide a survival benefit? – An insight from the GeroCovid registry. Thromb Haemost. 2022;122(1):105–12. https://doi.org/10.1055/a-1503-3875.

Protasiewicz M., Reszka K., Kosowski W. et al. Anticoagulation prior to COVID-19 infection has no impact on 6 months mortality: A propensity score-matched cohort study. J Clin Med. 2022;11(2):352. https://doi.org/10.3390/jcm11020352.

Gozzo L., Viale P., Longo L. et al. The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review. Front Pharmacol. 2020;11:1307. https://doi.org/10.3389/fphar.2020.01307.

Steffel J., Verhamme P., Potpara T.S.et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93. https://doi.org/10.1093/eurheartj/ehy136.

Foerster K.I., Hermann S., Mikus G., Haefeli W.E. Drug–drug interactions with direct oral anticoagulants. Clin Pharmacokinet. 2020;59(8):967–80. https://doi.org/10.1007/s40262-020-00879-x.

Cuker A., Tseng E.K., Nieuwlaat R. et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Adv. 2022;6(2):664–71. https://doi.org/10.1182/bloodadvances.2021005945.

Robinson S., Longmuir K., Pavord S. Haematology of pregnancy. Medicine. 2017;45(4):251–5. https://doi.org/10.1016.j.mpmed.2017.01.002.

D’Souza R., Malhamé I., Teshler L. et al. A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19. Acta Obstet Gynecol Scand. 2020;99(9):1110–20. https://doi.org/10.1111/aogs.13962.

Servante J., Swallow G., Thornton J.G. et al. Haemostatic and thromboembolic complications in pregnant women with COVID-19: a systematic review and critical analysis. BMC Pregnancy Childbirth. 2021;21(1):1–14. https://doi.org/10.1186/s12884-021-03568-0.

Daru J., White K., Hunt B.J. COVID-19, thrombosis and pregnancy.Thromb Update. 2021;5:100077. https://doi.org/10.1016/j.tru.2021.100077.

Lee Y.R., Blanco D.D. Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically ill patients. J Thromb Thrombolysis. 2017;44(3):386–91. https://doi.org/10.1007/s11239-017-1535-8.

Hendren N.S., De Lemos J.A., Ayers C. et al. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation. 2021;143(2):135–44. https://doi.org/10.1161/CIRCULATIONAHA.120.051936.

Sawadogo W., Tsegaye M., Gizaw A., Adera T. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: systematic review and meta-analysis. BMJ NutR Prev Health. 2022;5(1):10–8. https://doi.org/10.1136/bmjnph-2021-000375.

Hunt B.J. Hemostasis at extremes of body weight. Semin Thromb Hemost. 2018;44(7):632–9. https://doi.org/10.1055/s-0038-1661385.

Belančić A., Kresović A., Rački V. Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity. Obes Med. 2020;19:100259. https://doi.org/10.1016/j.obmed.2020.100259.

Wang T.-F., Milligan P.E., Wong C.A. et al. Efficacy and safety of highdose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111(1):88–93. https://doi.org/10.1160/TH13-01-0042.

He Z., Morrissey H., Ball P. Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients – Actual Weight-based vs Fixed. Crit Rev Oncol Hematol. 2017;113:191–4. https://doi.org/10.1016/j.critrevonc.2017.03.022.

Liu Y., Du X., Chen J. et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6–e12. https://doi.org/10.1016/j.jinf.2020.04.002.

Miranda S., Le Cam-Duchez V., Benichou J. et al. Adjusted value of thromboprophylaxis in hospitalized obese patients: a comparative study of two regimens of enoxaparin: the ITOHENOX study. Thromb Res. 2017;155:1–5. https://doi.org/10.1016/j.thromres.2017.04.011.

INSPIRATION Investigators; Sadeghipour P., Talasaz A., Rashidi F. et al. Eeffect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021;325(16):1620–30. https://doi.org/10.1001/jama.2021.4152.

Moores L.K., Tritschler T., Brosnahan S. et al. Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report. Chest. 2022;162(1):213–25. https://doi.org/10.1016/j.chest.2022.02.006.

Cohoon K.P., Mahé G., Tafur A.J., Spyropoulos A.C. Emergence of institutional antithrombotic protocols for coronavirus 2019. Res Pract Thromb Haemost. 2020;4(4):510–7. https://doi.org/10.1002/rth2.12358.

Stevens S.M., Woller S.C., Kreuziger L.B. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545–e608. https://doi.org/10.1016/j.chest.2021.07.055.

Wang Y., Zhu F., Wang C. et al. Children hospitalized with severe COVID-19 in Wuhan. Pediatr Infect Dis J. 2020;39(7):e91–e94. https://doi.org/10.1097/INF.0000000000002739.

Cruz A.T., Zeichner S.L. COVID-19 in children: initial characterization of the pediatric disease. Pediatrics. 2020;145(6):e20200834. https://doi.org/10.1542/peds.2020-0834.

Feldstein L.R., Rose E.B., Horwitz S.M. et al. Multisystem inflammatory syndrome in US children and adolescents. N Engl J Med. 2020;383(4):334–46. https://doi.org/10.1056/NEJMoa2021680.

Goldenberg N.A., Sochet A., Albisetti M. et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020;18(11):3099–105. https://doi.org/10.1111/jth.15073.

Sochet A.A., Morrison J.M., Jaffray J. et al. Enoxaparin thromboprophylaxis in children hospitalized for COVID-19: A phase 2 trial. Pediatrics. 2022;150(1):e2022056726. https://doi.org/10.1542/peds.2022-056726.

Shafiee M.A., Hosseini S.F., Mortazavi M. et al. Anticoagulation therapy in COVID-19 patients with chronic kidney disease. J Res Med Sci. 2021;26:63. https://doi.org/10.4103/jrms.JRMS_875_20.

Fernandez P., Saad E.J., Barrionuevo A.D. et al. The incidence, risk factors and impact of acute kidney injury in hospitalized patients due to COVID-19. Medicina (B Aires). 2021;81(6):922–30.

Stevens J.S., Velez J.C.Q., Mohan S. Continuous renal replacement therapy and the COVID pandemic. Semin Dial. 2021;34(6):561–6. https://doi.org/10.1111/sdi.12962.

Arnold F., Westermann L., Rieg S. et al. Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study. BMC Nephrol. 2020;21(1):486. https://doi.org/10.1186/s12882-020-02150-8.

Billett H., Reyes-Gil M., Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin and apixaban on mortality. Thromb Haemost. 2020;120(12):1691–9. https://doi.org/10.1055/s-0040-1720978.

Attallah N., Gupta S., Madhyastha R. et al. Anticoagulation in COVID-19 patients requiring continuous renal replacement therapy. Anaesth Crit Care Pain Med. 2021;40(3):100841. https://doi.org/10.1016/j.accpm.2021.100841.

Schünemann H.J., Cushman M.., Burnett A.E. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198–225. https://doi.org/10.1182/bloodadvances.2018022954.

PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group; Cook D., Meade M., Guyatt G. et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364(14):1305–14. https://doi.org/10.1056/NEJMoa1014475.

Perepu U.S., Chambers I., Wahab A. et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multicenter, open-label, randomized controlled trial. J Thromb Haemost. 2021;19(9):2225–34. https://doi.org/10.1111/jth.1545.

REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher E.C., Bradbury C.A., McVerry B.J. et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–89. https://doi.org/10.1056/NEJMoa2103417.

REMAP-CAP Writing Committee for the REMAP-CAP Investigators; Bradbury C.A., Lawler P.R., Stanworth S.J. et al. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1247–59. https://doi.org/10.1001/jama.2022.2910.

Bikdeli B., Talasaz A.H., Rashidi F. et al. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thromb Haemost. 2022;122(1):131–41. https://doi.org/10.1055/a-1485-2372.

Oliynyk O., Barg W., Slifirczyk A. et al. Comparison of the effect of unfractionated heparin and enoxaparin sodium at different doses on the course of COVID-19-associated coagulopathy. Life (Basel). 2021;11()10:1032. https://doi.org/10.3390/life11101032.

El-Ghiaty M.A, Shoieb S.M., El-Kadi A.O. Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms. Med Hypotheses. 2020;144:110033. https://doi.org/10.1016/j.mehy.2020.110033.

Vincent J.-L., Levi M., Hunt B.J. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med. 2021;10(2):214–20. https://doi.org/10.1016/S2213-2600(21)00455-0.

Roberts L.N., Whyte M.B., Georgiou L. et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020;136(11):1347–50. https://doi.org/10.1182/blood.2020008086.

Rashidi F., Barco S., Kamangar F. et al. Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study. Thromb Res. 2021;198:135–8. https://doi.org/10.1016/j.thromres.2020.12.001.

Patell R., Bogue T., Koshy A. et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;136(11):1342–6. https://doi.org/10.1182/blood.2020007938.

Giannis D., Allen S.L., Tsang J. et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021;137(20):2838–47. https://doi.org/10.1182/blood.2020010529.

Lui D.T.W., Li Y.K., Lee C.H. et al. A prospective study of the impact of glycaemic status on clinical outcomes and anti-SARS-CoV-2 antibody responses among patients with predominantly non-severe COVID-19. Diabetes Res Clin Pract. 2022;185:109232. https://doi.org/10.1016/j.diabres.2022.109232.

Chioh F.W., Fong S.-W., Young B.E. et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. Elife. 2021;10:e64909. https://doi.org/10.7554/eLife.6490.

Spyropoulos A.C., Cohen S.L., Gianos E. et al. Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. Res Pract Thromb Haemost. 2021;5(2):296–300. https://doi.org/10.1002/rth2.12486.

Goldin M., Lin S.K., Kohn N. et al. External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. J Thromb Thrombolysis. 2021;52(4):1032–5. https://doi.org/10.1007/s11239-021-02504-5.

Ramacciotti E., Agati L.B., Calderaro D. et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399(10319):50–9. https://doi.org/10.1016/S0140-6736(21)02392-8.

The authors declare that there are no conflicts of interest present.